BioSpace News Archive

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.

The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.

Algernon Pharmaceuticals Inc. is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx.

According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.

Singapore, 27 March, 2024 - INEX Innovate is excited to share that its groundbreaking product, OvaCis® Rapid Test, has received regulatory approval from the Health Sciences Authority (HSA) in Singapore.

OXFORD, UK, and CHICAGO, USA 27 March 2024 – Brainomix, the AI-powered medtech company, announces the publication of a new study in the prestigious peer-reviewed journal American Journal of Respiratory and Critical Care Medicine (AJRCCM)1, resulting from a research collaboration AstraZeneca, the UK’s leading Biopharmaceutical company.

Hoth Therapeutics, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Chemical Insights Research Institute of UL Research Institutes has released its first report on a multi-phase research study of per- and polyfluoroalkyl substances, commonly referred to as “forever chemicals,” associated with consumer and commercial textiles.